84.66 USD
+0.99 (+1.18%)
84.61 USD
-0.05 (-0.06%)
CORT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. CORT gets an excellent profitability rating and is at the same time showing great financial health properties. CORT is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, CORT could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
In the past 5 years CORT has always been profitable.
In the past 5 years CORT always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of CORT (12.88%) is better than 93.23% of its industry peers.
The Return On Equity of CORT (16.79%) is better than 90.10% of its industry peers.
CORT's Return On Invested Capital of 8.69% is amongst the best of the industry. CORT outperforms 87.50% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 17.94%. This is significantly above the industry average of 12.71%.
The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(8.69%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROIC | 8.69% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
CORT has a Profit Margin of 14.32%. This is amongst the best in the industry. CORT outperforms 86.46% of its industry peers.
CORT's Profit Margin has declined in the last couple of years.
The Operating Margin of CORT (8.85%) is better than 80.21% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
CORT's Gross Margin of 98.19% is amongst the best of the industry. CORT outperforms 97.40% of its industry peers.
CORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CORT is creating value.
Compared to 1 year ago, CORT has more shares outstanding
Compared to 5 years ago, CORT has less shares outstanding
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 30.62 indicates that CORT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 30.62, CORT belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 30.62 |
ROIC/WACC0.96
WACC9.05%
2.3 Liquidity
CORT has a Current Ratio of 3.14. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CORT (3.14) is comparable to the rest of the industry.
A Quick Ratio of 3.07 indicates that CORT has no problem at all paying its short term obligations.
With a Quick ratio value of 3.07, CORT perfoms like the industry average, outperforming 54.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 |
3. Growth
3.1 Past
The earnings per share for CORT have decreased strongly by -30.16% in the last year.
CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.71% yearly.
CORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.92%.
The Revenue has been growing by 17.11% on average over the past years. This is quite good.
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
3.2 Future
Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 54.42% on average per year.
Based on estimates for the next years, CORT will show a very strong growth in Revenue. The Revenue will grow by 31.49% on average per year.
EPS Next Y-17.95%
EPS Next 2Y27.38%
EPS Next 3Y64.99%
EPS Next 5Y54.42%
Revenue Next Year23.1%
Revenue Next 2Y28.9%
Revenue Next 3Y31.29%
Revenue Next 5Y31.49%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CORT is valuated quite expensively with a Price/Earnings ratio of 96.20.
Based on the Price/Earnings ratio, CORT is valued a bit cheaper than the industry average as 77.08% of the companies are valued more expensively.
CORT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.41.
The Price/Forward Earnings ratio is 42.08, which means the current valuation is very expensive for CORT.
70.31% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.40, CORT is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96.2 | ||
| Fwd PE | 42.08 |
4.2 Price Multiples
CORT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CORT is cheaper than 76.04% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than the industry average as 77.08% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.78 | ||
| EV/EBITDA | 123.32 |
4.3 Compensation for Growth
The excellent profitability rating of CORT may justify a higher PE ratio.
CORT's earnings are expected to grow with 64.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)9.9
EPS Next 2Y27.38%
EPS Next 3Y64.99%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
84.66
+0.99 (+1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners76.03%
Inst Owner Change-1.12%
Ins Owners6.58%
Ins Owner Change-0.01%
Market Cap8.91B
Revenue(TTM)741.17M
Net Income(TTM)106.11M
Analysts82
Price Target137.93 (62.92%)
Short Float %10.94%
Short Ratio12.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.91%
Min EPS beat(2)16.19%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)11.15%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)17.67%
EPS beat(12)9
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)12.14%
Revenue beat(2)0
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-6.85%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-8.72%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)-4.4%
Revenue beat(8)4
Avg Revenue beat(8)-2.84%
Revenue beat(12)6
Avg Revenue beat(12)-1.78%
Revenue beat(16)7
Avg Revenue beat(16)-2.44%
PT rev (1m)0%
PT rev (3m)0.54%
EPS NQ rev (1m)-6%
EPS NQ rev (3m)-25.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.35%
Revenue NQ rev (1m)-8%
Revenue NQ rev (3m)-10.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96.2 | ||
| Fwd PE | 42.08 | ||
| P/S | 12.02 | ||
| P/FCF | 54.78 | ||
| P/OCF | 54.69 | ||
| P/B | 14.09 | ||
| P/tB | 14.09 | ||
| EV/EBITDA | 123.32 |
EPS(TTM)0.88
EY1.04%
EPS(NY)2.01
Fwd EY2.38%
FCF(TTM)1.55
FCFY1.83%
OCF(TTM)1.55
OCFY1.83%
SpS7.05
BVpS6.01
TBVpS6.01
PEG (NY)N/A
PEG (5Y)9.9
Graham Number10.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROCE | 10.07% | ||
| ROIC | 8.69% | ||
| ROICexc | 24.92% | ||
| ROICexgc | 24.92% | ||
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% | ||
| FCFM | 21.93% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexgc growth 3Y-18.86%
ROICexgc growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.2% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 245.43% | ||
| Profit Quality | 153.21% | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 | ||
| Altman-Z | 30.62 |
F-Score6
WACC9.05%
ROIC/WACC0.96
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
EPS Next Y-17.95%
EPS Next 2Y27.38%
EPS Next 3Y64.99%
EPS Next 5Y54.42%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
Revenue Next Year23.1%
Revenue Next 2Y28.9%
Revenue Next 3Y31.29%
Revenue Next 5Y31.49%
EBIT growth 1Y-54.26%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-34.64%
EBIT Next 3Y41.42%
EBIT Next 5Y19.15%
FCF growth 1Y5.22%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y5.34%
OCF growth 3Y5.66%
OCF growth 5Y7.79%
CORCEPT THERAPEUTICS INC / CORT FAQ
What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CORT.
What is the valuation status for CORT stock?
ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.
Can you provide the profitability details for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.
What is the financial health of CORCEPT THERAPEUTICS INC (CORT) stock?
The financial health rating of CORCEPT THERAPEUTICS INC (CORT) is 8 / 10.